Postmenopausal Osteoporosis Treatment Market To Reach $13.7 Billion By 2030

Postmenopausal Osteoporosis Treatment Market Growth & Trends

The global postmenopausal osteoporosis treatment market size is expected to reach USD 13.7 billion by 2030 and is expected to expand at a CAGR of 5.22% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market has grown significantly as a result of the growing geriatric population and lifestyle changes. As the older population is more susceptible, their population growth is anticipated to be a major driving force behind the market expansion. For instance, the number of people aged 60 years and above is predicted to rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050, according to the World Health Organization's October 2021 report. As a result, the market is anticipated to expand during the forecast period due to a rise in demand for postmenopausal osteoporosis treatment among older people.

In addition, lifestyle modifications like inactivity, excessive alcohol consumption, smoking, long work hours, and unhealthy eating patterns have an impact on menopause and increase the risk of osteoporosis in many women around the globe. Furthermore, age, smoking, alcohol consumption, and the use of drugs to address illnesses like gonadotropins, excessive thyroid hormone use, & cytotoxic agents are a few of the risk factors that can lead to low bone density and the development of the condition in women after menopause. Thus, it will drive the market growth. In 2021, more than 200 million women were affected with osteoporosis, and 1 in 3 women over 50 years of age are predicted to sustain an osteoporosis fracture, according to statistics from the International Menopause Society (IMS). As a result of the aforementioned factors, it is anticipated that the studied market will expand over the projected period.

However, it is anticipated that during the projection era, low awareness about the disease will impede industry growth. In the forecast period, there will likely be a significant increase in research and development efforts as a result of investments made by industry participants and research institutions. For instance, according to the information posted on clinicaltrial.gov, as of June 2021, there were approximately 25 ongoing phase III as well as phase IV clinical trials for osteoporosis medications in the U.S. Consequently, as a result of the aforementioned factors, the market is expected to grow over the forecast period. For instance, Eli Lilly and Company is creating blosozumab, a humanized IgG4 monoclonal antibody, to treat postmenopausal osteoporosis. It is an inhibitor of the SOST protein and is presently undergoing phase II clinical studies.

 Request a free sample copy or view report summary: Postmenopausal Osteoporosis Treatment Market Report

Postmenopausal Osteoporosis Treatment Market Report Highlights

• By drug class, the bisphosphonate segment accounted for the largest share in 2022

• Bisphosphonates have several benefits, including the ability to stop bone thinning, increase bone strength, preserve bone structure, and lower the chance of fracture in people with osteoporosis

• By distribution channel, the hospital pharmacy segment accounted for the largest share in 2022. The market is expanding as a result of the high hospitalization rate associated with the target disease

• North America held the largest share in 2022 due to the strong presence of key market participants, as well as rising R&D spending and federal assistance, in the region

• Asia Pacific is expected to grow at the highest CAGR over the projected period due to the rising prevalence of target disease, the growing aging population, and the increasing adoption of postmenopausal osteoporosis treatments

Postmenopausal Osteoporosis Treatment Market Segmentation

Grand view research has segmented the global postmenopausal osteoporosis treatment market based on drug type, distribution channel, and region:

Postmenopausal Osteoporosis Treatment Drug Type Outlook (Revenue, USD Million, 2018 - 2030)

• Bisphosphonates

• Vitamin D3

• Estrogen Agonist/Antagonist

• Hormone Replacement Therapy

• Parathyroid Hormone Therapy

• Others

Postmenopausal Osteoporosis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Postmenopausal Osteoporosis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Postmenopausal Osteoporosis Treatment Market

• Teva Pharmaceuticals Industries Ltd.

• Pfizer Inc.

• Merck & Co.

• Novartis AG

• Eli Lilly and Company

• AbbVie (Allergan plc.)

• Cipla Inc.

• Amgen Inc.

• F. Hoffmann-La Roche Ltd.